The DOI matches its Crossref record; 126 of the 126 references it cites were found in a registry or an index.
Cannabinoids for nausea and vomiting in adults with cancer receiving chemotherapy
Open accessAbstract
BACKGROUND: Cannabis has a long history of medicinal use. Cannabis-based medications (cannabinoids) are based on its active element, delta-9-tetrahydrocannabinol (THC), and have been approved for medical purposes. Cannabinoids may be a useful therapeutic option for people with chemotherapy-induced nausea and vomiting that respond poorly to commonly used anti-emetic agents (anti-sickness drugs). However, unpleasant adverse effects may limit their widespread use. OBJECTIVES: To evaluate the effectiveness and tolerability of cannabis-based medications for chemotherapy-induced nausea and vomiting in adults with cancer. SEARCH METHODS: We identified studies by searching the following electronic databases: Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, PsycINFO and LILACS from inception to January 2015. We also searched reference lists of reviews and included studies. We did not restrict the search by language of publication. SELECTION CRITERIA: We included randomised controlled trials (RCTs) that compared a cannabis-based medication with either placebo or with a conventional anti-emetic in adults receiving chemotherapy. DATA COLLECTION AND ANALYSIS: At least two review authors independently conducted eligibility and risk of bias assessment, and extracted data. We grouped studies based on control groups for meta-analyses conducted using random effects. We expressed efficacy and tolerability outcomes as risk ratio (RR) with 95% confidence intervals (CI). MAIN RESULTS: We included 23 RCTs. Most were of cross-over design, on adults undergoing a variety of chemotherapeutic regimens ranging from moderate to high emetic potential for a variety of cancers. The majority of the studies were at risk of bias due to either lack of allocation concealment or attrition. Trials were conducted between 1975 and 1991. No trials involved comparison with newer anti-emetic drugs such as ondansetron. Comparison with placebo People had more chance of reporting complete absence of vomiting (3 trials; 168 participants; RR 5.7; 95% CI 2.6 to 12.6; low quality evidence) and complete absence of nausea and vomiting (3 trials; 288 participants; RR 2.9; 95% CI 1.8 to 4.7; moderate quality evidence) when they received cannabinoids compared with placebo. The percentage of variability in effect estimates that was due to heterogeneity rather than chance was not important (I(2) = 0% in both analyses).People had more chance of withdrawing due to an adverse event (2 trials; 276 participants; RR 6.9; 95% CI 1.96 to 24; I(2) = 0%; very low quality evidence) and less chance of withdrawing due to lack of efficacy when they received cannabinoids, compared with placebo (1 trial; 228 participants; RR 0.05; 95% CI 0.0 to 0.89; low quality evidence). In addition, people had more chance of 'feeling high' when they received cannabinoids compared with placebo (3 trials; 137 participants; RR 31; 95% CI 6.4 to 152; I(2) = 0%).People reported a preference for cannabinoids rather than placebo (2 trials; 256 participants; RR 4.8; 95% CI 1.7 to 13; low quality evidence). Comparison with other anti-emetics There was no evidence of a difference between cannabinoids and prochlorperazine in the proportion of participants reporting no nausea (5 trials; 258 participants; RR 1.5; 95% CI 0.67 to 3.2; I(2) = 63%; low quality evidence), no vomiting (4 trials; 209 participants; RR 1.11; 95% CI 0.86 to 1.44; I(2) = 0%; moderate quality evidence), or complete absence of nausea and vomiting (4 trials; 414 participants; RR 2.0; 95% CI 0.74 to 5.4; I(2) = 60%; low quality evidence). Sensitivity analysis where the two parallel group trials were pooled after removal of the five cross-over trials showed no difference (RR 1.1; 95% CI 0.70 to 1.7) with no heterogeneity (I(2) = 0%).People had more chance of withdrawing due to an adverse event (5 trials; 664 participants; RR 3.9; 95% CI 1.3 to 12; I(2) = 17%; low quality evidence), due to lack of efficacy (1 trial; 42 participants; RR 3.5; 95% CI 1.4 to 8.9; very low quality evidence) and for any reason (1 trial; 42 participants; RR 3.5; 95% CI 1.4 to 8.9; low quality evidence) when they received cannabinoids compared with prochlorperazine.People had more chance of reporting dizziness (7 trials; 675 participants; RR 2.4; 95% CI 1.8 to 3.1; I(2) = 12%), dysphoria (3 trials; 192 participants; RR 7.2; 95% CI 1.3 to 39; I(2) = 0%), euphoria (2 trials; 280 participants; RR 18; 95% CI 2.4 to 133; I(2) = 0%), 'feeling high' (4 trials; 389 participants; RR 6.2; 95% CI 3.5 to 11; I(2) = 0%) and sedation (8 trials; 947 participants; RR 1.4; 95% CI 1.2 to 1.8; I(2) = 31%), with significantly more participants reporting the incidence of these adverse events with cannabinoids compared with prochlorperazine.People reported a preference for cannabinoids rather than prochlorperazine (7 trials; 695 participants; RR 3.3; 95% CI 2.2 to 4.8; I(2) = 51%; low quality evidence).In comparisons with metoclopramide, domperidone and chlorpr
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1. The Cochrane Collaboration
Higgins, J. P. T., Green, S. R., & Higgins, J. P. T. (2008) · Cited by 7,175
Isolation and Structure of a Brain Constituent That Binds to the Cannabinoid Receptor
Devane, W. A., Hanuš, L., Breuer, A., Pertwee, R. G., Stevenson, L. A., Griffin, G., Gibson, D., Mandelbaum, A., Etinger, A., & Mechoulam, R. (1992) · Science · doi:10.1126/science.1470919 · Cited by 5,633
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913
2-Arachidonoylgylcerol: A Possible Endogenous Cannabinoid Receptor Ligand in Brain
Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., & Waku, K. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2437 · Cited by 2,196
Deeks, J. J., Altman, D. G., & Bradburn, M. J. (2001) · Systematic Reviews in Health Care · doi:10.1002/9780470693926.ch15 · Cited by 2,163
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
Basch, E., Prestrud, A. A., Hesketh, P. J., Kris, M. G., Feyer, P. C., Somerfield, M. R., Chesney, M., Clark-Snow, R. A., Flaherty, A. M., Freundlich, B., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.4614 · Cited by 1,059
Cannabinoids: potential anticancer agents
Guzmán, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1188 · Cited by 703
Roila, F., Herrstedt, J., Aapro, M., Gralla, R. J., Einhorn, L. H., Ballatori, E., Bria, E., Clark-Snow, R. A., Espersen, B. T., Feyer, P., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq194 · Cited by 680
Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines
Gralla, R. J., Osoba, D., Kris, M. G., Kirkbride, P., Hesketh, P. J., Chinnery, L. W., Clark-Snow, R., Gill, D. P., Groshen, S., Grunberg, S., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2971 · Cited by 664
Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review
Tramèr, M. R., Carroll, D., Campbell, F. A., Reynolds, D. J. M., Moore, R. A., & McQuay, H. J. (2001) · BMJ · doi:10.1136/bmj.323.7303.16 · Cited by 610
Cannabinoids in medicine: A review of their therapeutic potential
Ben Amar, M. (2006) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2006.02.001 · Cited by 543
Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action
Zuardi, A. W. (2008) · Revista Brasileira de Psiquiatria · doi:10.1590/s1516-44462008000300015 · Cited by 421 · cited 2×
“Zuardi 2008 {published data only} Zuardi AW.”
BackgroundTHE ENDOCANNABINOID SYSTEM: PHYSIOLOGY AND PHARMACOLOGY
RODRÍGUEZ de FONSECA, F., DEL ARCO, I., BERMUDEZ-SILVA, F. J., BILBAO, A., CIPPITELLI, A., & NAVARRO, M. (2005) · Alcohol and Alcoholism · doi:10.1093/alcalc/agh110 · Cited by 407
Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists
de Boer-Dennert, M., de Wit, R., Schmitz, P., Djontono, J., v Beurden, V, Stoter, G., & Verweij, J. (1997) · British Journal of Cancer · doi:10.1038/bjc.1997.507 · Cited by 378
Antiemetic Effect of Delta-9-Tetrahydrocannabinol in Patients Receiving Cancer Chemotherapy
Sallan, S. E., Zinberg, N. E., & Frei, E. (1975) · New England Journal of Medicine · doi:10.1056/nejm197510162931603 · Cited by 364
Adverse effects of medical cannabinoids: a systematic review
Wang, T., Collet, J.-P., Shapiro, S., & Ware, M. A. (2008) · Canadian Medical Association Journal · doi:10.1503/cmaj.071178 · Cited by 357
Sallan, S. E., Cronin, C., Zelen, M., & Zinberg, N. E. (1980) · New England Journal of Medicine · doi:10.1056/nejm198001173020302 · Cited by 261
CHANG, A. E., SHILING, D. J., STILLMAN, R. C., GOLDBERG, N. H., SEIPP, C. A., BAROFSKY, I., SIMON, R. M., & ROSENBERG, S. A. (1979) · Annals of Internal Medicine · doi:10.7326/0003-4819-91-6-819 · Cited by 259
Therapeutic Potential of Cannabinoids in CNS Disease
Croxford, J. L. (2003) · CNS Drugs · doi:10.2165/00023210-200317030-00004 · Cited by 240
Recent clinical experience with dronabinol
Plasse, T. F., Gorter, R. W., Krasnow, S. H., Lane, M., Shepard, K. V., & Wadleigh, R. G. (1991) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(91)90385-f · Cited by 224
MACHADO ROCHA, F. C., STÉFANO, S. C., DE CÁSSIA HAIEK, R., ROSA OLIVEIRA, L. M. Q., & DA SILVEIRA, D. X. (2008) · European Journal of Cancer Care · doi:10.1111/j.1365-2354.2008.00917.x · Cited by 223
Ioannidis, J. P. A., Hesketh, P. J., & Lau, J. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.19.3409 · Cited by 223
Herman, T. S., Einhorn, L. H., Jones, S. E., Nagy, C., Chester, A. B., Dean, J. C., Furnas, B., Williams, S. D., Leigh, S. A., Dorr, R. T., et al. (1979) · New England Journal of Medicine · doi:10.1056/nejm197906073002302 · Cited by 216
Meiri, E., Jhangiani, H., Vredenburgh, J. J., Barbato, L. M., Carter, F. J., Yang, H.-M., & Baranowski, V. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x167525 · Cited by 214
FRYTAK, S., MOERTEL, C. G., O'FALLON, J. R., RUBIN, J., CREAGAN, E. T., O'CONNELL, M. J., SCHUTT, A. J., & SCHWARTAU, N. W. (1979) · Annals of Internal Medicine · doi:10.7326/0003-4819-91-6-825 · Cited by 201
Current pharmacotherapy for chemotherapy-induced nausea and vomiting in cancer patients
Janelsins, M. C., Tejani, M. A., Kamen, C. S., Peoples, A. R., Mustian, K. M., & Morrow, G. R. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.776541 · Cited by 187
(1998) · Annals of Oncology · doi:10.1023/a:1008471812316 · Cited by 185
Durán, M., Pérez, E., Abanades, S., Vidal, X., Saura, C., Majem, M., Arriola, E., Rabanal, M., Pastor, A., Farré, M., et al. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03743.x · Cited by 166
Established and potential therapeutic applications of cannabinoids in oncology
Walsh, D., Nelson, K. A., & Mahmoud, F. (2003) · Supportive Care in Cancer · doi:10.1007/s00520-002-0387-7 · Cited by 163
Development of reliable and valid measures of nausea and vomiting
RHODES, V. A., WATSON, P. M., & JOHNSON, M. H. (1984) · Cancer Nursing · doi:10.1097/00002820-198402000-00003 · Cited by 162
Darmani, N. N. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00197-4 · Cited by 145
Medicinal Applications of Delta-9-Tetrahydrocannabinol and Marijuana
Voth, E. A., & Schwartz, R. H. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-126-10-199705150-00008 · Cited by 145
Chemotherapy-Induced Nausea and Vomiting
Lohr, L. (2008) · The Cancer Journal · doi:10.1097/ppo.0b013e31816a0f07 · Cited by 144
Update and new trends in antiemetic therapy: the continuing need for novel therapies
Feyer, P. C., & Jordan, K. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq600 · Cited by 143
Toward drugs derived from cannabis
Mechoulam, R., & Carlini, E. A. (1978) · Die Naturwissenschaften · doi:10.1007/bf00450585 · Cited by 140
Phillips, R. S., Friend, A. J., Gibson, F., Houghton, E., Gopaul, S., Craig, J. V., & Pizer, B. L. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007786.pub3 · Cited by 135
Lane, M., Vogel, C. L., Ferguson, J., Krasnow, S. H., Saiers, J. L., Hamm, J. T., Salva, K., Wiernik, P. H., Holroyde, C. P., Hammill, S., et al. (1991) · Journal of Pain and Symptom Management · doi:10.1016/0885-3924(91)90026-z · Cited by 112
Antiemetics: an update and the MASCC guidelines applied in clinical practice
Herrstedt, J. (2007) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1021 · Cited by 110
Nabilone: an alternative antiemetic for cancer chemotherapy.
Dalzell, A. M., Bartlett, H., & Lilleyman, J. S. (1986) · Archives of Disease in Childhood · doi:10.1136/adc.61.5.502 · Cited by 98
AMELIORATION OF CANCER CHEMOTHERAPY‐INDUCED NAUSEA AND VOMITING BY DELTA‐9‐TETRAHYDRO‐CANNABINOL
Ekert, H., Waters, K., Jurk, I., Mobilia, J., & Loughnan, P. M. (1979) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1979.tb127271.x · Cited by 97
On the Pharmacological Properties of Δ9‐Tetrahydrocannabinol (THC)
Costa, B. (2007) · Chemistry & Biodiversity · doi:10.1002/cbdv.200790146 · Cited by 96
Chan, H. S. L., Correia, J., & MacLeod, S. M. (1987) · PEDIATRICS · doi:10.1542/peds.79.6.946 · Cited by 95
Comparative activity of antiemetic drugs
Jordan, K., Schmoll, H., & Aapro, M. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2006.08.003 · Cited by 95
Shiling, D. J., Stillman, R. C., Chang, A. E., Goldberg, N. H., Seipp, C. A., Barofsky, I., & Rosenberg, S. A. (1981) · Cancer · Cited by 94
Oral nabilone capsules in the treatment of chemotherapy-induced nausea and vomiting and pain
Davis, M. P. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.1.85 · Cited by 94
A review of nabilone in the treatment of chemotherapy-induced nausea and vomiting
Ware, M. A. (2008) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s1132 · Cited by 92
Nabilone: An Effective Antiemetic in Patients Receiving Cancer Chemotherapy
Einhorn, L. H., Nagy, C., Furnas, B., & Williams, S. D. (1981) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1981.tb02576.x · Cited by 91
Orr, L. E. (1980) · Archives of Internal Medicine · doi:10.1001/archinte.140.11.1431 · Cited by 91
Pharmacological Management of Chemotherapy-Induced Nausea and Vomiting: Focus on Recent Developments
Navari, R. M. (2009) · Drugs · doi:10.2165/00003495-200969050-00002 · Cited by 91
Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy
Ahmedzai, S. H., Carlyle, D., Calder, I. T., & Moran, F. (1983) · British Journal of Cancer · doi:10.1038/bjc.1983.247 · Cited by 88
Gralla, R. J., Tyson, L. B., Bordin, L. A., Clark, R. A., Kelsen, D. P., Kris, M. G., Kalman, L., & Groshen, S. G. (1984) · PubMed · Cited by 87
Use of Conjoint Analysis to Assess Breast Cancer Patient Preferences for Chemotherapy Side Effects
Beusterien, K. M., Grinspan, J., Kuchuk, I., Mazzarello, S., Dent, S. F., Gertler, S. Z., Bouganim, N., Vandermeer, L., & Clemons, M. J. (2014) · The Oncologist · doi:10.1634/theoncologist.2013-0359 · Cited by 84
Review of cannabinoids and their antiemetic effectiveness
Vincent, B. J., McQuiston, D. J., Einhorn, L. H., Nagy, C. M., & Brames, M. J. (1983) · Drugs · doi:10.2165/00003495-198300251-00006 · Cited by 83
Cohen, J. L., Jorizzo, J. L., & Kircik, L. (2007) · PubMed · Cited by 79
Cannabinoid-Induced Hyperemesis: A Conundrum—From Clinical Recognition to Basic Science Mechanisms
Darmani, N. A. (2010) · Pharmaceuticals · doi:10.3390/ph3072163 · Cited by 75
Sun, C. C., Bodurka, D. C., Donato, M. L., et al. (2002) · Gynecologic Oncology · doi:10.1006/gyno.2002.6807 · Cited by 74
Anemia in cancer: update on studies of erythropoiesis-stimulating agents.
Schwartzberg, L. S. (2007) · PubMed · Cited by 72
Advances in anti-emetic therapy
Bakowski, M. T. (1984) · Cancer Treatment Reviews · doi:10.1016/0305-7372(84)90010-0 · Cited by 72
Efficacy of tetrahydrocannabinol in patients refractory to standard antiemetic therapy
McCabe, M., Smith, F. P., Macdonald, J. S., Woolley, P. V., Goldberg, D., & Schein, P. S. (1988) · Investigational New Drugs · doi:10.1007/bf00175407 · Cited by 70
STEELE, N. E., Gralla, R. J., Dw, B., & Cw, Y. (1980) · PubMed · Cited by 70
Anti-emetic drugs in oncology: pharmacology and individualization by pharmacogenetics
Perwitasari, D. A., Gelderblom, H. A. J., Thobari, J. A., Mustofa, M., Dwiprahasto, I., Nortier, J. W. R., & Guchelaar, H. (2011) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-010-9454-1 · Cited by 66
Antiemetic Effect of Tetrahydrocannabinol
Orr, L. E. (1980) · Archives of Internal Medicine · doi:10.1001/archinte.1980.00330220019010 · Cited by 66
Musty, R. E., & Rossi, R. (2001) · Journal of Cannabis Therapeutics · doi:10.1300/j175v01n01_03 · Cited by 65
Mechoulam, R., & Hanus, L. O. (2001) · Pain Research and Management · doi:10.1155/2001/183057 · Cited by 61
Pomeroy, M., FENNELLY, J. J., & Towers, M. J. (1986) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00256701 · Cited by 59
Ward, A., & Holmes, B. (1985) · Drugs · doi:10.2165/00003495-198530020-00002 · Cited by 59
Cunningham, D., Bradley, C. J., Forrest, G. J., Hutcheon, A. W., Adams, L., Sneddon, M., Harding, M., Kerr, D., Soukop, M., & Kaye, S. B. (1988) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(88)90300-8 · Cited by 58
Comparative Trial of the Antiemetic Effects of THC and Haloperidol
Neidhart, J. A., Gagen, M. M., Wilson, H. E., & Young, D. C. (1981) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1981.tb02571.x · Cited by 56
Johansson, R. T., Kilkku, P., & Groenroos, M. (1982) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(82)80032-7 · Cited by 54
Orr, L. E., & Mckernan, J. (1981) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1981.tb02578.x · Cited by 54
A cross-over comparison of nabilone and prochlorperazine for emesis induced by cancer chemotherapy
Niiranen, A., & Mattson, K. V. (1985) · American Journal of Clinical Oncology · doi:10.1097/00000421-198508000-00013 · Cited by 54
Naturally Occurring and Related Synthetic Cannabinoids and their Potential Therapeutic Applications
Galal, A. M., Slade, D., Gul, W., El‐Alfy, A. T., Ferreira, D., & ElSohly, M. A. (2009) · Recent Patents on CNS Drug Discovery · doi:10.2174/157488909788453031 · Cited by 54
Delta-9-Tetrahydrocannabinol in Cancer Chemotherapy: Research Problems and Issues
Carey, M. P., Burish, T. G., & Brenner, D. E. (1983) · Annals of Internal Medicine · doi:10.7326/0003-4819-99-1-106 · Cited by 50
Antiemetic Effect of Intramuscular Levonantradol in Patients Receiving Anticancer Chemotherapy
Cronin, C. M., Sallan, S. E., Gelber, R. D., Lucas, V. S., & László, J. (1981) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1981.tb02572.x · Cited by 50
Jones, S. E., Durant, J. R., Greco, F. A., & Robertone, A. B. (1982) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(82)80035-2 · Cited by 47
Crawford, S. M., & Buckman, R. A. (1986) · Medical Oncology and Tumor Pharmacotherapy · doi:10.1007/bf02934575 · Cited by 46
Cancer Cachexia and Cannabinoids
Gorter, R. W. (1999) · Complementary Medicine Research · doi:10.1159/000057152 · Cited by 46
Nelemans, J. K., Neleman, F. A., Meuwissen, O. J., & Maes, R. A. A. (1979) · PubMed · Cited by 43
Double-blind, randomized, crossover trial of nabilone vs. placebo in cancer chemotherapy
Wada, J. K., Bogdon, D. L., Gunnell, J. C., Hum, G. J., Gota, C. H., & Rieth, T. E. (1982) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(82)80034-0 · Cited by 42
Meyer, J. S., & Connor, R. E. (1982) · Cancer · doi:10.1002/1097-0142(19820815)50:4<636::aid-cncr2820500404>3.0.co;2-4 · Cited by 41
Δ9-Tetrahydrocannabinol in Clinical Oncology
Poster, D. S. (1981) · JAMA · doi:10.1001/jama.1981.03310450039020 · Cited by 41
Niederle, N., Schütte, J., & Schmidt, C. G. (1986) · Journal of Molecular Medicine · doi:10.1007/bf01728184 · Cited by 41
Colls, B. M., Ferry, D. G., Gray, A. J., Vj, H., & McQueen, E. G. (1980) · PubMed · Cited by 41
Pharmacology and Toxicology of Cannabis Derivatives and Endocannabinoid Agonists
Gerra, G., Zaimovic, A., Gerra, M. L., Ciccocioppo, R., Cippitelli, A., Serpelloni, G., & Somaini, L. (2009) · Recent Patents on CNS Drug Discovery · doi:10.2174/157488910789753521 · Cited by 40
Phillips, R. S., Gopaul, S., Gibson, F., Houghton, E., Craig, J. V., Light, K., & Pizer, B. L. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007786.pub2 · Cited by 40
Lane, M., Smith, F. E., Sullivan, R. A., & Plasse, T. F. (1990) · American Journal of Clinical Oncology · doi:10.1097/00000421-199012000-00006 · Cited by 38
The emerging role of cannabinoid neuromodulators in symptom management
Davis, M. P., Maida, V., Daeninck, P. J., & Pergolizzi, J. V. (2006) · Supportive Care in Cancer · doi:10.1007/s00520-006-0180-0 · Cited by 37
Nabilone and prochlorperazine: a useful combination for emesis induced by cytotoxic drugs.
Cunningham, D., Forrest, G. J., Soukop, M., Gilchrist, N. L., Calder, I. T., & McArdle, C. (1985) · BMJ · doi:10.1136/bmj.291.6499.864 · Cited by 36
Antiemetic control: toward a new standard of care for emetogenic chemotherapy
Navari, R. M. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560902731894 · Cited by 35
Nabilone vs. placebo in the treatment of chemotherapy-induced nausea and vomiting in cancer patients
Levitt, M. (1982) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(82)80036-4 · Cited by 34
Corticosteroids, dopamine antagonists and other drugs
Herrstedt, J., Aapro, M., Smyth, J. F., & Favero, A. D. (1998) · Supportive Care in Cancer · doi:10.1007/s005200050155 · Cited by 33
Antiemetic Efficacy of Nabilone and Dexamethasone
Niiranen, A., & Mattson, K. V. (1987) · American Journal of Clinical Oncology · doi:10.1097/00000421-198708000-00014 · Cited by 32
Treatment of nausea and vomiting caused by cancer chemotherapy
László, J. (1982) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(82)80029-7 · Cited by 32
Methodologic issues in trials of antiemetics.
Pater, J. L., & Willan, A. R. (1984) · Journal of Clinical Oncology · doi:10.1200/jco.1984.2.5.484 · Cited by 32
THC or Compazine® for the cancer chemotherapy patient—the UCLA study
Ungerleider, J. T., Fairbanks, L. A., Andrysiak, T., Sarna, G. P., Goodnight, J. E., & Jamison, K. R. (1985) · American Journal of Clinical Oncology · doi:10.1097/00000421-198504000-00006 · Cited by 31
Hutcheon, A. W., Palmer, J. B. D., Soukop, M., Cunningham, D., McArdle, C. S., Welsh, J., Stuart, F., Sangster, G., Kaye, S. B., Charlton, D., et al. (1983) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(83)90032-9 · Cited by 30
Cotter, J. (2009) · Oncology nursing forum · doi:10.1188/09.onf.345-352 · Cited by 29
Clinical Trials with Antiemetic Agents in Cancer Patients Receiving Chemotherapy
Penta, J. S., Poster, D. S., Bruno, S., & Macdonald, J. S. (1981) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1981.tb02568.x · Cited by 28
Baker, J., Lokey, J. L., Price, N. A., Winokur, S. H., Bowen, J., & Taylor, A. (1979) · New England Journal of Medicine · doi:10.1056/nejm197909273011318 · Cited by 28
THE CONTROL OF CANCER CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING
Dodds, L. J. (1985) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.1985.tb01129.x · Cited by 26
Pharmacologic Treatment of Chemotherapy-Induced Nausea and Vomiting
Fiore, J. J., & Gralla, R. J. (1984) · Cancer Investigation · doi:10.3109/07357908409040312 · Cited by 24
Citron, M. L., Ts, H., Vreeland, F., Krasnow, S. H., Fossieck, B. E., Harwood, S., Franklin, R., & Mh, C. (1985) · PubMed · Cited by 23
Stambaugh, J. E., McAdams, J., & Vreeland, F. (1984) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1984.tb02756.x · Cited by 22
Mechanisms and management of chemotherapy-induced nausea and vomiting
Allan, S. G. (1987) · Blood Reviews · doi:10.1016/0268-960x(87)90019-1 · Cited by 20
Sheidler, V. R., Ettinger, D. S., Diasio, R. B., Enterline, J. P., & Brown, M. D. (1984) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1984.tb01824.x · Cited by 20
Heim, M. E., Quei�er, W., & Altenburg, H.-P. (1984) · Cancer Chemotherapy and Pharmacology · doi:10.1007/bf00257128 · Cited by 18
George, M., Mh, P., Thuaire, M., Kramar, A., & Jp, W. (1983) · PubMed · Cited by 18
A Critical Review of the Safety and Antiemetic Efficacy of Delta-9-Tetrahydrocannabinol
Cocchetto, D. M., Cook, L. F., & Cato, A. E. (1981) · Annals of Pharmacotherapy · doi:10.1177/106002808101501104 · Cited by 16
CANNABIS AND CANCER CHEMOTHERAPY
Colls, B. M. (1980) · The Lancet · doi:10.1016/s0140-6736(80)91642-6 · Cited by 15
Therapeutic potential of cannabinoids.
Bateman, D. N., & Rawlins, M. D. (1982) · BMJ · doi:10.1136/bmj.284.6324.1211-a · Cited by 15
Comparative Efficacy of Dronabinol and Megestrol Acetate
Reynolds, R., Jatoi, A., Loprinzi, C. L., & Windschitl, H. E. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.12.2912 · Cited by 14
Levitt, M., WILSON, A., BOWMAN, D., Kemel, S., Krepart, G. V., Marks, V., Schipper, H., Thomson, G. T. D., Weinerman, B., & WEINERMAN, R. (1981) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1981.tb02583.x · Cited by 13
Adverse reactions to delta-9-tetrahydrocannabinol given as an antiemetic in a multicenter study.
Ml, D., Gj, D., Br, G., Dw, H., Icaza, L., Py, J., Fh, M., O'Brien, E., Roberts, C. M., & Gl, R. (1987) · PubMed · Cited by 13
Higi, M., Niederle, N., Bremer, K., Schmitt, G., Schmidt, C. G., & Seeber, S. (2008) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-2008-1070107 · Cited by 11
Grunberg, S. M. (1989) · Blood Reviews · doi:10.1016/0268-960x(89)90029-5 · Cited by 11
Use of nabilone in the treatment of chemotherapy-induced vomiting in an outpatient setting
Cone, L. A., Greene, D., & Helm, N. A. (1982) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(82)80038-8 · Cited by 10
Antiemetic study design: desirable objectives, stratifications and analyses.
In, O. (1992) · Europe PMC (PubMed Central) · Cited by 10
Delta-9-tetrahydrocannabinol as an antiemetic
Anderson, P. O., & McGuire, G. G. (1981) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/38.5.639 · Cited by 10
Marijuana for Drug-Induced Nausea and Vomiting
Sweet, D. L. (1980) · JAMA · doi:10.1001/jama.1980.03300380045025 · Cited by 9
Recent advances in the prevention or reduction of cytotoxic‐induced emesis
Kearsley, J. H., & Tattersall, M. H. N. (1985) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1985.tb123059.x · Cited by 8
Levonantradol for the treatment of chemotherapy-induced nausea and vomiting
Gerhartz, H. H., Binsack, T., & Hiller, E. (1983) · Journal of Molecular Medicine · doi:10.1007/bf01487619 · Cited by 6
A kemoterápia okozta hányás csillapítása
Tóth, J., & Szántó, J. (2008) · Magyar Onkológia · doi:10.1556/monkol.52.2008.4.9 · Cited by 2
Neue Aspekte der antiemetischen Therapie bei Zytostatika-induziertem Erbrechen
Hiller, E., & Gerhartz, H. H. (1984) · Journal of Molecular Medicine · doi:10.1007/bf01726904 · Cited by 2
Jhangiani, H. S., Vredenburgh, J. J., Barbato, L., Yang, H., Yang, H.-M., Baranowski, V., & Tse, N. (2005) · Blood · doi:10.1182/blood.v106.11.5555.5555 · Cited by 2
Cited by
Hall, W., Stjepanović, D., Caulkins, J., Lynskey, M., Leung, J., Campbell, G., & Degenhardt, L. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31789-1 · Cited by 357
Solmi, M., De Toffol, M., Kim, J. Y., Choi, M. J., Stubbs, B., Thompson, T., Firth, J., Miola, A., Croatto, G., Baggio, F., et al. (2023) · BMJ · doi:10.1136/bmj-2022-072348 · Cited by 271
Cannabis sativa: Much more beyond Δ9-tetrahydrocannabinol
Alves, P., Amaral, C., Teixeira, N., & Correia-da-Silva, G. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104822 · Cited by 135
Tafelski, S., Häuser, W., & Schäfer, M. (2016) · Der Schmerz · doi:10.1007/s00482-015-0092-3 · Cited by 71
Psychotic disorder and cannabis use: Canadian hospitalization trends, 2006–2015
Maloney-Hall, B., Wallingford, S. C., Konefal, S., & Young, M. M. (2020) · Health Promotion and Chronic Disease Prevention in Canada · doi:10.24095/hpcdp.40.5/6.06 · Cited by 21
Metadata
- Authors
- Smith, L. A., Azariah, F., Lavender, V. T., Stoner, N. S., & Bettiol, S.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2015-11-12
- Volume
- 2021
- Issue
- 11
- Pages
- CD009464-CD009464
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W2172339395
- Cited by
- 255
- References
- 126
- FWCI
- 17.57
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.